Literature DB >> 16638369

Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center.

Laura Atzori1, Anna Luisa Pinna, Caterina Ferreli, Nicola Aste.   

Abstract

Pityriasis rosea is a common, acute eruption of uncertain etiology. A rash very similar to this idiopathic disease is also attributed to several drugs, and recovery, which depends on withdrawal of the responsible drug, can be delayed by its late identification. A prospective study to record all cases of adverse cutaneous reactions presenting with pityriasis rosea like manifestations was conducted at the center for drug-surveillance of the dermatology department of Cagliari University. We developed an intensive surveillance program from June 2002 to May 2005, adopting the WHO Collaborating center for Drug Monitoring causality assessment criteria and algorithm. Eight cases, six male and two female, were studied in a 3-year period. None had previously suffered from drug intolerance or allergy. Clinical manifestations were very similar to pityriasis rosea. Responsible drugs were mainly angiotensin-converting enzyme inhibitors, alone or in combination with hydrochlorothiazide, followed by one case each for hydrochlorothiazide plus sartan, allopurinol, nimesulide, acetyl salicylic acid. Recovery was obtained in all cases with drug withdrawal. Final causality assessment was probable for all eruptions. Frequency of drug pityriasis rosea-like eruptions is probably underreported. The mildness of the eruption, mimicking a very common and self-limiting disease does not prompt physicians to verify the use of medications until persistence, severity of lesions and itching require re-evaluation of the original diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16638369

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  7 in total

1.  Angiotensin-II mediates nonmuscle myosin II activation and expression and contributes to human keloid disease progression.

Authors:  Jennifer E Bond; Andrew Bergeron; Peter Thurlow; M Angelica Selim; Edith V Bowers; Anna Kuang; Howard Levinson
Journal:  Mol Med       Date:  2011-07-21       Impact factor: 6.354

2.  Atypical Pityriasis Rosea with Unilateral Presentation.

Authors:  Hoda Badakhsh; Fahameh Fadaei; Mahin Badakhsh; Abbas Balouchi
Journal:  J Clin Diagn Res       Date:  2016-12-01

3.  [Cutaneous drug reactions imitating dermatoses].

Authors:  N Magnolo; T Schwarz; S Ständer
Journal:  Hautarzt       Date:  2014-05       Impact factor: 0.751

4.  Pityriasis rosea like drug rash - a need to identify the disease in childhood.

Authors:  Maitreyee Panda; Nibedita Patro; Monalisa Jena; Mrutunjay Dash; Swati Mishra
Journal:  J Clin Diagn Res       Date:  2014-08-20

5.  Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy.

Authors:  E Farinazzo; G Ponis; E Zelin; E Errichetti; G Stinco; C Pinzani; A Gambelli; N De Manzini; L Toffoli; A Moret; M Agozzino; C Conforti; N Di Meo; P Schincariol; I Zalaudek
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-07       Impact factor: 9.228

6.  Nomenclature of drug-induced pityriasis rosea-like rashes.

Authors:  Antonio At Chuh
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-03       Impact factor: 2.570

Review 7.  Pityriasis Rosea: An Update on Etiopathogenesis and Management of Difficult Aspects.

Authors:  Khushbu Mahajan; Vineet Relhan; Aditi Kochhar Relhan; Vijay Kumar Garg
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.